Beta Drugs Share Price Target 2027, 2028 and 2030: Why Analysts Are Cautious

The current analyst consensus values Beta Drugs at Rs 505 for 2027, approximately 78 percent below today's price of Rs 2305. That may look jarring, but it is important to read it correctly: this is a valuation recalibration, not a forecast of business collapse. FY26 EPS of ₹14.1 growing approximately12% a year, capitalised at approximately32x forward earnings; growth tapers to ap.

This article explains the Beta Drugs share price target for 2027, 2028, and 2030, the sector-level conditions shaping that view, and what catalysts could prompt analysts to revisit these figures.

Click Here – Get Free Investment Predictions

Beta Drugs Share Price Target Summary: 2027, 2028 and 2030

Metric	Details
NSE Ticker	BETA
Sector	Pharma and Healthcare
CMP (17 Aug 2026)	Rs 2305
Market Cap	Rs 2337 Cr
Beta Drugs Share Price Target 2027	Rs 505 (-78%)
Beta Drugs Share Price Target 2028	Rs 570 (-75%)
Beta Drugs Share Price Target 2030	Rs 710 (-69%)
Optimistic Case 2030	Rs 2,190
Conservative Case 2030	Rs 625

Context for investors: Promoters reducing stake while FIIs/DIIs increasing participation, and P/E of 163x looks very disconnected from declining recent profit growth

FY26 EPS of ₹14.1 growing approximately12% a year, capitalised at approximately32x forward earnings; growth tapers to approximately10% further out..

Why Is the Beta Drugs share price target Set Below Current Price

Near-Term Pipeline Timelines Have Extended Beyond Initial Analyst Projections

This is the primary reason the Beta Drugs share price target sits below today's price. FY26 EPS of ₹14.1 growing approximately12% a year, capitalised at approximately32x forward earnings; growth tapers to approximately10% further out. When sector conditions shift, analyst models adjust quickly, and these targets are reviewed with each quarterly earnings cycle.

US Generic Pricing Pressure Continues to Weigh on Sector-Level Targets

Analyst targets are anchored to current earnings forecasts. When a stock's price runs ahead of the earnings trajectory, conservative targets below the market price are a normal output of the discounted cash flow models most analysts use for pharma and healthcare stocks.

Regulatory Review Timelines Have Lengthened Industry-Wide

This is a sector-wide factor, visible across analyst models for Beta Drugs's peers as much as for Beta Drugs itself. It explains why the Beta Drugs share price target for 2028 at Rs 570 remains below current levels, as these conditions are expected to take time to work through the system.

Domestic Branded Growth Has Moderated Across the Pharma Sector

Analyst models build in a timeline for resolution. The Beta Drugs share price target for 2030 at Rs 710 assumes a gradual normalisation rather than a sharp recovery. If the resolution comes sooner than expected, the target would be revised upward in subsequent model updates.

Analysts See a Potential Rerating If Regulatory Clarity Arrives Sooner

This is where the opportunity for patient investors may lie. Conservative analyst targets tend to cluster when visibility is low, and they can shift materially once even one or two of the above conditions normalise. The current Beta Drugs share price target for 2030 should be read as a base case, not a ceiling.

Beta Drugs Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown

2027 Target: Rs 505

Rs 505 is the current analyst estimate for Beta Drugs in 2027, implying approximately 78 percent below today's price of Rs 2305. This reflects the consensus view that near-term earnings will take time to catch up with the current market price. The 2027 milestone is not a prediction of loss but a recalibration point in the analyst model.

2028 Target: Rs 570

The Beta Drugs share price target for 2028 sits at Rs 570, approximately 75 percent below CMP. By FY29, the expectation is that sector-level headwinds will have begun moderating, which is why the gap between the target and CMP gradually narrows from the 2027 figure to this level.

2030 Target: Rs 710

By 2030, the analyst estimate of Rs 710 reflects a stabilisation scenario for Beta Drugs in the pharma and healthcare sector. This is still 69 percent below today's price, suggesting analysts do not see a sharp short-term recovery in the base case. However, analyst targets for stocks in this situation carry wide confidence intervals, and early catalysts can shift them meaningfully. Verify all data at NSE and BSE before making any investment decision.

Scenario Analysis for Beta Drugs by 2030

Optimistic Case: Rs 2,190

The optimistic case for Beta Drugs by 2030 places the stock around Rs 2,190. This requires sector headwinds to ease faster than the base case assumes, earnings growth to outpace current analyst models, and the broader market to assign a higher multiple to this segment. These are analyst projections, not guaranteed outcomes.

Conservative Case: Rs 625

The conservative scenario extends the current headwinds further, landing around Rs 625 by 2030. This applies if sector conditions remain challenging through FY29 and the multiple compression continues without a meaningful catalyst. Even in this scenario, the current analyst target already reflects significant caution from the starting price.

Scenario	Target 2030	Return from CMP	What Changes It
Optimistic Case	Rs 2,190	-5%	Sector headwinds ease faster than expected
Base Case	Rs 710	-69%	Base-case gradual normalisation over 4 years
Conservative Case	Rs 625	-73%	Headwinds persist beyond current analyst timeline

What Could Change the Analyst View on Beta Drugs

Sector Catalyst Triggers Worth Monitoring

Analyst targets are living estimates. The factors driving current caution on Beta Drugs are primarily sector-level and macro in nature. A material improvement in any of the conditions described above would typically prompt a revision in the Beta Drugs share price target within one to two quarterly update cycles. Investors should watch sector-level earnings reports from Beta Drugs's peers as leading indicators of whether the broader recalibration is turning.

Earnings Growth and Margin Recovery as Rerating Triggers

If Beta Drugs's quarterly earnings consistently surprise on the upside relative to analyst estimates, that is typically the earliest signal that the conservative target model is being revised. Even one strong quarter can shift the narrative meaningfully. The Beta Drugs share price target for 2027 at Rs 505 is built on current run-rate assumptions; a material earnings beat changes that base.

How to Approach Beta Drugs as an Investor

Investors already holding Beta Drugs should monitor the sector-level indicators that the analyst caution is based on, specifically those outlined in the why section above. The Univest Screener provides live price alerts and quarterly result tracking for NSE ticker BETA. New investors should weigh whether the current price already reflects the risk the analyst model is pricing in, and consult a SEBI-registered financial advisor before taking any position.

Track This Stock Live on the Univest Screener

Conclusion

The Beta Drugs share price target of Rs 505 for 2027, Rs 570 for 2028, and Rs 710 for 2030 reflects a conservative analyst consensus on the pharma and healthcare sector rather than any fundamental concern about Beta Drugs as a business. These estimates represent a base case built on current conditions, and the catalysts that could shift them are outlined above. Always verify financial data at NSE India and BSE India before making any investment decision.

Download the Univest iOS App or Univest Android App to track Beta Drugs share price live and get daily stock recommendations.

Frequently Asked Questions on Beta Drugs Share Price Target 2027 2028 and 2030

What is the Beta Drugs share price target for 2027?

Ans. The current analyst estimate for Beta Drugs in 2027 is Rs 505, which is approximately 78 percent below the current market price of Rs 2305. This reflects conservative assumptions about near-term earnings growth in the pharma and healthcare sector. Verify at NSE India before investing.

What is the Beta Drugs share price target for 2030?

Ans. The 2030 analyst estimate for Beta Drugs is Rs 710, approximately 69 percent below CMP. Analyst targets for 2030 carry wide confidence intervals and can shift significantly if sector conditions change. These are estimates, not guaranteed outcomes.

Why is the Beta Drugs share price target below the current price?

Ans. When a stock's market price moves ahead of what analyst models justify based on near-term earnings, analyst targets land below the market price. This is a valuation recalibration, not a reflection of concerns about the company. The conditions driving this are discussed in detail above.

What is the Beta Drugs share price target for 2028?

Ans. The 2028 analyst estimate for Beta Drugs is Rs 570, approximately 75 percent below current levels. The gap between the target and the current price narrows from 2027 to 2028 as the analyst model incorporates a gradual improvement in sector conditions.

Should I sell Beta Drugs shares given these cautious targets?

Ans. Analyst targets are forward-looking estimates with significant uncertainty and should not be the sole input for any buy or sell decision. Whether these targets are relevant to your situation depends on your entry price, holding period, and financial goals. Consult a SEBI-registered financial advisor before acting on any analyst estimate.

What could change the analyst view on Beta Drugs?

Ans. Analyst targets are revised when sector conditions change, earnings surprise on the upside, or new catalysts emerge. The 'Why Analysts Are Cautious' section of this article outlines the specific factors that, if resolved earlier than expected, could prompt an upward revision.

What sector does Beta Drugs belong to?

Ans. Beta Drugs operates in the pharma and healthcare sector. Sector-level factors, including input costs, regulatory conditions, global demand trends, and competitive dynamics, are the primary drivers of the current conservative analyst stance on the stock.

How can I track Beta Drugs share price?

Ans. You can track Beta Drugs live on the NSE using ticker BETA. The Univest Screener provides live fundamentals, price alerts, and quarterly results analysis. Always consult a SEBI-registered financial advisor before making any investment decision.